Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 22Squamous Cell Carcinoma of Head and Neck 13Carcinoma, Non-Small-Cell Lung 12Neoplasms 6Rectal Neoplasms 5Neoplasm Metastasis 5Mouth Neoplasms 5Lung Neoplasms 5Head and Neck Neoplasms 5Colonic Neoplasms 5Pancreatic Neoplasms 4Laryngeal Neoplasms 3Hypopharyngeal Neoplasms 3Carcinoma, Squamous Cell 3Carcinoma 3Thyroid Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Ovarian Neoplasms 2Oropharyngeal Neoplasms 2Endometrial Neoplasms 2Urologic Neoplasms 1Solid Tumors 1Soft Tissue Neoplasms 1Skin Neoplasms 1Sarcoma 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pharyngeal Neoplasms 1Neurofibromatosis 2 1Neurofibromatosis 1 1

Interventions

fludarabine phosphate 2fludarabine 2blinatumomab 2Cyclophosphamide 2tislelizumab 1tisagenlecleucel 1obinutuzumab 1Radiotherapy 1Monatide (IMS 3015) 1HMPL-013 1Cetuximab 1Blood Specimen Collection 1Biological Assay 1AP 1903 reagent 1ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm, Residual × Cetuximab × 30 days × Clear all
NCT06358430 2026-05-20

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

M.D. Anderson Cancer Center

Phase 1 Recruiting
42 enrolled
Gastrointestinal

Colorectal Neoplasms, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡